Scorpius Holdings, Inc. announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a major university. The program involves process optimization and development of a therapeutic antibody, which Scorpius will manufacture for preclinical studies. The work will be conducted in the Company's process development lab and cGMP cleanrooms in its Mammalian Building, which is ideally suited for early-stage programs using CHO cell lines.

Following process optimization and development, the Company expects to expand the scope of the agreement to include Phase 1 clinical manufacturing.